Methyl 3-[2-(4-chlorobenzoyl)-6-hydroxy-1-benzofuran-3-yl]propanoate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Methyl 3-[2-(4-chlorobenzoyl)-6-hydroxy-1-benzofuran-3-yl]propanoate
• 化学式: C₁₉H₁₅ClO₅
• 分子量: 358.8
• InChiKey: PZCGHURHKFOPPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  76.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] A PROCESS FOR THE PREPARATION OF ANTI-INFLAMMATORY AROYLBENZOFURAN COMPOUNDS<br/>[FR] PROCÉDÉ DE PRÉPARATION DE COMPOSÉS D'AROYLBENZOFURANNE ANTI-INFLAMMATOIRES
  申请人：COUNCIL OF SCIENT AND IND RSEARCH

  公开号：WO2015029062A1

  公开（公告）日：2015-03-05

  Disclosed herein an efficient process for synthesis of benzofuran analogues having anti-inflammatory activity which comprises, Ru-catalyzed branched and linear selective alkylation of aroylbenzofurans formula-I with alpha, beta unsaturated esters of formula-II via C-H activation in presence of base, additives and organic solvent at suitable temperature to give high yield of desired linear alkylated benzofuran compounds of formula-III or branched alkylated benzofuran compounds of formula-IV or mixture thereof.

  本文披露了一种高效合成具有抗炎活性的苯并呋喃类似物的过程，包括在碱、添加剂和有机溶剂的存在下，通过Ru催化的分支和线性选择性芳基苯并呋喃式-I与式-II的α，β不饱和酯进行烷基化反应，通过C-H活化在适当温度下，以高产率得到所需的线性烷基化苯并呋喃化合物式-III或分支烷基化苯并呋喃化合物式-IV或二者的混合物。
• NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION
  申请人：Barlow Carrolee

  公开号：US20070049576A1

  公开（公告）日：2007-03-01

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  该即时披露描述了通过刺激或增加神经发生来治疗中枢神经系统和外周神经系统的疾病和病症的方法。该披露包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经生成剂结合以刺激或激活新神经细胞的形成。
• Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
  申请人：Nycomed GmbH

  公开号：EP1849468A2

  公开（公告）日：2007-10-31

  The invention relates to the combined administration of PDE4 or PDE3/4 inhibitors and histamine receptor antagonists for the treatment of respiratory diseases.

  本发明涉及联合使用 PDE4 或 PDE3/4 抑制剂和组胺受体拮抗剂治疗呼吸系统疾病。
• Methods of inducing ovulation using a non-polypeptide camp level modulator
  申请人：Laboratoires Serono SA

  公开号：EP1908463A2

  公开（公告）日：2008-04-09

  The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulator include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.

  本发明涉及诱导雌性宿主排卵的方法，包括向雌性宿主施用非多肽环磷酸腺苷（cAMP）水平调节剂。在另一方面，本发明提供了在宿主排卵周期的黄体期之前特异性给药磷酸二酯酶抑制剂的方法。优选的非多肽cAMP水平调节剂包括磷酸二酯酶抑制剂，特别是磷酸二酯酶4同工酶抑制剂。
• Synergistic combination
  申请人：Nycomed GmbH

  公开号：EP2193808A1

  公开（公告）日：2010-06-09

  The invention relates to the combined administration of PDE inhibitors and β2 adrenoceptor agonists for the treatment of respiratory tract disorders.

  本发明涉及联合使用 PDE 抑制剂和 β2 肾上腺素受体激动剂治疗呼吸道疾病。